This website is intended for healthcare professionals only

Trending Topic

5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The 12th European Stroke Organisation Conference (Maastricht, May 6–8, 2026) was dominated by studies testing the limits of acute stroke therapy, from thrombectomy and neuroprotection to secondary prevention. Supplementary Table 1 provides a comprehensive overview of the major studies presented during the conference. The large-core indication for thrombectomy is recent, and the ATLAS (Endovascular thrombectomy […]

Neuroimmunology

An Introduction to Neuroimmunology

Supported by:
EUROPEAN PARTNER
A detailed medical illustration depicting the nervous system affected by multiple sclerosis.
Mark CompleteCompleted
BookmarkBookmarked

Phase 3 data presented at MSToronto2026 strengthen the case for oral, central nervous system-penetrant Bruton’s tyrosine kinase inhibition in multiple sclerosis. However, differences between individual agents, limited head-to-head data with high-efficacy therapies, and unanswered questions around long-term disability and safety ...

45 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Global excluding UK, USA and Canada.

Join MS-specialist neurologists, Dr Izanne Roos and Dr Wallace Brownlee, as they share their highlights from MSToronto 2026, 10th Joint ACTRIMS-ECTRIMS congress.

elearning
Mark CompleteCompleted
BookmarkBookmarked

Explore the National Multiple Sclerosis Society’s new interactive eLearning program, designed to help clinicians understand and apply the 2024 McDonald Criteria in clinical practice The 2024 revisions to the McDonald Criteria represent a substantial evolution in the diagnosis of multiple sclerosis (...

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS
Dr. Eoin Flanagan

Expert insights into recognizing and diagnosing MOGAD and differentiating it from related demyelinating diseases.

Neuron neuroprotection: glucagon-like peptide-1 (GLP-1) molecular barrier shielding nerve cell from amyloid beta plaques. Alzheimer's and Parkinson’s disease therapy. Neuroscience, cognitive health
Mark CompleteCompleted
BookmarkBookmarked

Highlights from the European Academy of Neurology (EAN) 2026 Congress included new phase 3 data in ocular myasthenia gravis, emerging migraine treatments, longer-term results in multiple sclerosis, and advances in deep brain stimulation for Parkinson’s disease. The 12th Congress of the ...

Mark CompleteCompleted
BookmarkBookmarked

Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...

Mark CompleteCompleted
BookmarkBookmarked

We are delighted to announce Dr Ahmed Abdelhak as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in blood biomarkers in multiple sclerosis. We spoke with Dr Ahmed Abdelhak (Department of ...

Mark CompleteCompleted
BookmarkBookmarked

We are delighted to announce Dr Elias Sotirchos as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neuroimmunological disorders research We spoke with Dr Elias Sotirchos (Johns Hopkins University School of Medicine, ...

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

An expert highlights unmet needs in gMG and the potential of targeted therapies to improve patient outcomes.

broad rim lesions
Mark CompleteCompleted
BookmarkBookmarked

Dr Joost Smolders discusses the biology of broad rim lesions, their association with faster disability accumulation and how they could help inform future prognostication and treatment strategies in multiple sclerosis. Emerging biomarkers capable of identifying patients at risk of rapid ...

31 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: USA only

Watch this program to gain expert perspectives on MMN and CIDP, including diagnostic challenges and disease burden.

44 mins
Sponsored Content

Watch this program to learn about FcRn blockade and its role in the treatment of gMG and CIDP, with insights from expert faculty.

30

A bitesize microlearning series exploring modalities to uncover multiple sclerosis (MS) progression without overt relapses. Each bite-sized module equips clinicians to spot early symptoms, detect MS specific mechanisms, and to refine patient management.

ACTRIMS
Mark CompleteCompleted
BookmarkBookmarked

Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...

Mark CompleteCompleted
BookmarkBookmarked

Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...

Mark CompleteCompleted
BookmarkBookmarked

New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...

Mark CompleteCompleted
BookmarkBookmarked

New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent ...

Conference
Mark CompleteCompleted
BookmarkBookmarked

The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...

Load More...
Close Popup